All In Biotech

Drug Trial Radar · NCT06501534

A Dose Finding Study to Assess Efficacy and Safety of IBI128 in Chinese Gout Subjects

A Randomized, Open Label, Multicenter, Parallel-group, Positive-controlled, Dose Finding, and Phase II Study to Assess Efficacy and Safety of IBI128 in Chinese Gout Subjects

Last checked: Nov 20, 2026Latest source record: Mar 27, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

84

Actual

Start

Jul 10, 2024

Primary completion

Dec 13, 2024

Study completion Jan 9, 2025

Sponsor

Sponsor type
Industry
First posted
Jul 15, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

IBI128 (Tigulixostat) is a novel non-purine selective inhibitor of xanthine oxidase (XO). The XO inhibitors lower uric acid concentrations in serum by inhibiting the production of uric acid. This ia a randomized, open label, multicenter, parallel-group, positive-controlled, dose finding, and Phase II study to assess efficacy and safety of IBI128 in chinese gout subjects.

Conditions

  • Gout
  • Hyperuricemia

Interventions

  • FebuxostatDrug

    Tablets, Once a day (QD), Per oral

  • IBI128Drug

    Other Names: LC350189, Tigulixostat,Tablets, Once a day (QD), Per oral

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. The proportion of subjects in each treatment group with serum uric acid levels <360 μmol/L after continuous treatment for 16 weeksTime frame: Week 16

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Shanghai Fudan University HuaShan Hospital

    Shanghai, Shanghai Municipality, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.